A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD)
Tekijät: Charalambous Andreas, Tsitsi Theologia, Astras George, Paikousis Lefkios, Filippou Elena
Kustantaja: Churchill Livingstone
Julkaisuvuosi: 2021
Journal: European Journal of Oncology Nursing
Tietokannassa oleva lehden nimi: European journal of oncology nursing : the official journal of European Oncology Nursing Society
Lehden akronyymi: Eur J Oncol Nurs
Artikkelin numero: 101866
Vuosikerta: 50
ISSN: 1462-3889
eISSN: 1532-2122
DOI: https://doi.org/10.1016/j.ejon.2020.101866
Purpose
Palmar-Plantar Erythrodysesthesia (PPE) is a dose-limiting adverse event that commonly occurs with capecitabine and Pegylated Liposomal Doxorubicin-PLD treatment. The study aimed to test the effectiveness of a Pyridoxine (B6) treatment protocol in the management of PPE in patients receiving treatment with capecitabine or pegylated liposomal doxorubicin.
Methods
This was a pilot randomized double-blind, placebo-controlled study. Patients receiving capecitabine or pegylated liposomal doxorubicin with PPE grade 1 or above were randomly allocated to receive pyridoxine or placebo. The PPE grade, Quality of Life-QoL, Pain and patients’ activities of daily living were assessed.
Results
Thirty patients were assigned in the Control and 24 in the Intervention group. No statistically significant difference was found in the PPE grade between baseline and week 6 in the 2 groups (p = 0.263). The control group exhibited worst PPE-associated QoL and higher PAIN levels between baseline and week 6. Respectively, the intervention group showed improved PPE-associated QoL and lower PAIN levels. At week 6, the ECOG status in the Intervention group was improved compared to the control (p = 0.018). Patients in the Intervention group experienced better Global Health Status (p = 0.012), Physical (p = 0.003), Emotional (p = 0.008), and Social function (p < 0.001), lower Fatigue (p = 0.001) and Pain (p = 0.006) compared to Control.
Conclusion
Topical pyridoxine was not shown to have an effect on the treatment of PPE. However, results demonstrated its effectiveness on health related QoL, QoL-associated with PPE and pain levels. Due to the high attrition rate further validation of these results in a larger population is warranted.
